A case of multiple immune toxicities from Ipilimumab and pembrolizumab treatment

Hormones (Athens). 2016 Apr;15(2):303-306. doi: 10.14310/horm.2002.1656.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Antibodies, Monoclonal / adverse effects*
  • Antibodies, Monoclonal, Humanized / adverse effects*
  • Diabetes Mellitus, Type 1 / chemically induced*
  • Diabetes Mellitus, Type 1 / diagnosis
  • Diabetes Mellitus, Type 1 / immunology
  • Humans
  • Hypophysitis / chemically induced*
  • Hypophysitis / diagnosis
  • Hypophysitis / immunology
  • Ipilimumab
  • Male
  • Melanoma / drug therapy*
  • Melanoma / immunology
  • Melanoma / secondary
  • Middle Aged
  • Risk Factors
  • Skin Neoplasms / drug therapy*
  • Skin Neoplasms / immunology
  • Skin Neoplasms / pathology

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Ipilimumab
  • pembrolizumab